Based on the results of this study, we propose that the pre- and post-administration of HSA-Trx could be therapeutically beneficial in the treatment of rhabdomyolysis-induced AKI as a consequense of its long-lasting anti-oxidative, anti-inflammatory and anti-apoptotic action. This evidence concerns the gene TXN and acute kidney injury.